Normal vision. Courtesy NIH National Eye InstituteThe same view with tunnel vision from retinitis pigmentosa
Find information on thousands of medical conditions and prescription drugs.

Retinitis pigmentosa

Retinitis pigmentosa, or RP, is a genetic eye condition. Generally, night blindness precedes tunnel vision by years or even decades. Many people with RP do not become legally blind until their 40s or 50s and retain some sight all their life. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
Gastroesophageal reflux...
Rabies
Radiophobia
Rasmussen's encephalitis
Raynaud's phenomenon
Reactive arthritis
Reactive hypoglycemia
Reflex sympathetic...
Regional enteritis
Reiter's Syndrome
Renal agenesis
Renal artery stenosis
Renal calculi
Renal cell carcinoma
Renal cell carcinoma
Renal cell carcinoma
Renal failure
Renal osteodystrophy
Renal tubular acidosis
Repetitive strain injury
Respiratory acidosis
Restless legs syndrome
Retinitis pigmentosa
Retinoblastoma
Retinoschisis
Retrolental fibroplasia
Retroperitoneal fibrosis
Rett syndrome
Reye's syndrome
Rh disease
Rhabdomyolysis
Rhabdomyosarcoma
Rheumatic fever
Rheumatism
Rheumatoid arthritis
Rickets
Rift Valley fever
Ringworm
Rocky Mountain spotted fever
Romano-Ward syndrome
Roseola infantum
Rubella
Rubeola
Rubinstein-Taybi syndrome
Rumination disorder
S
T
U
V
W
X
Y
Z
Medicines

Others go completely blind from RP, in some cases as early as childhood. Progression of RP is different in each case.

RP is a group of inherited disorders in which abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium (RPE) of the retina lead to progressive visual loss. Affected individuals first experience defective dark adaptation or nyctalopia (night blindness), followed by constriction of the peripheral visual field and, eventually, loss of central vision late in the course of the disease.

Signs

Mottling of the retinal pigment epithelium with bone-spicule pigmentation is typically pathognomonic for retinis pigmentosa. Other ocular features include waxy pallor of the optic nerve head, attenuated retinal vessels, cellophane maculopathy, cystic macular edema, and posterior subcapsular cataract.

Diagnosis

The diagnosis of RP relies upon documentation of progressive loss in photoreceptor function by electroretinography (ERG) and visual field testing. The mode of inheritance of RP is determined by family history. At least 35 different genes or loci are known to cause nonsyndromic RP. DNA testing is available on a clinical basis for RLBP1 (autosomal recessive, Bothnia type RP), RP1 (autosomal dominant, RP1), RHO (autosomal dominant, RP4), RDS (autosomal dominant, RP7), PRPF8 (autosomal dominant, RP13), PRPF3 (autosomal dominant, RP18), CRB1 (autosomal recessive, RP12), ABCA4 (autosomal recessive, RP19), and RPE65 (autosomal recessive, RP20). For all other genes, molecular genetic testing is available on a research basis only.

RP can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. X-linked RP can be either recessive, affecting primarily only males, or dominant, affecting both males and females, although females are always more mildly affected. Some digenic and mitochondrial forms have also been described. Genetic counseling depends on an accurate diagnosis, determination of the mode of inheritance in each family, and results of molecular genetic testing. RP combined with progressive deafness is called Usher syndrome.

Treatment

There is currently no medical treatment for retinitis pigmentosa, although scientists continue to investigate possible treatments. Future treatments may involve retinal transplants, artificial retinal implants , gene therapy, stem cells, nutritional supplements, and/or drug therapies.

Sources

Jones BW, CB Watt, JM Frederick, W Baehr, CK Chen, EM Levine, AH Milam, MM LaVail, RE Marc 2003 Retinal remodeling triggered by photoreceptor degenerations. J Comp Neurol 464: 1-16.

Marc RE, BW Jones 2003 Retinal remodeling in inherited photoreceptor degenerations. Molecular Neurobiology 28: 139-148.

Read more at Wikipedia.org


[List your site here Free!]


Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa
From Alternative Medicine Review, 11/1/03 by DH Wheaton

BACKGROUND: In a 4-year placebo-controlled trial to elevate blood docosahexaenoic acid levels in patients with X-linked retinitis pigmentosa (XLRP), the goal was to assess the potential benefit of docosahexaenoic acid supplementation in altering disease progression. However, docosahexaenoic acid (22:6omega3) is a highly unsaturated fatty acid and considered a target molecule for free-radical oxidative damage. Thus, nutritional provision of docosahexaenoic acid might lead to an increase in antioxidant stress. Additional concerns, such as decreased platelet aggregation, increased bleeding time, and alterations in lipoprotein cholesterol levels, have been reported in supplementation studies with long-chain polyunsaturates. OBJECTIVE: To assess the biological safety of long-term docosahexaenoic acid supplementation. DESIGN: Forty-four male patients (mean age, 16 years) enrolled in a randomized, double-masked, clinical trial and received docosahexaenoic acid, 400 mg/d, or placebo. Blood samples were collected every 6 months. Biological safety analysis included fatty acids, vitamin A and E concentrations, antioxidant capacity, platelet aggregation, alanine aminotransferase activity, and lipoprotein cholesterol and triglyceride profiles. RESULTS: Mean plasma docosahexaenoic acid levels were elevated 2.5-fold by supplementation compared with baseline. Patients receiving placebo capsules exhibited no change (P =.35) in plasma docosahexaenoic acid content. All adverse events reported were minor and equivalently distributed between groups. Plasma vitamin A concentrations remained unchanged during the trial. Mean plasma vitamin E concentrations were correlated with age (P =.005), such that as patients with XLRP matured, plasma vitamin E concentrations increased to approach normal values. There was a trend (P =.10) toward lower mean vitamin E concentrations in the docosahexaenoic acid-supplemented group after 4 years. Docosahexaenoic acid supplementation did not compromise plasma antioxidant capacity, platelel aggregation, liver function enzyme activity, or plasma lipoprotein lipid content in patients with XLRP. CONCLUSION: Long-term docosahexaenoic acid supplementation to patients with XLRP was associated with no identifiable safety risks in this 4-year clinical trial.

COPYRIGHT 2003 Thorne Research Inc.
COPYRIGHT 2003 Gale Group

Return to Retinitis pigmentosa
Home Contact Resources Exchange Links ebay